Therapeutic Nipple Sparing Mastectomy.

Inclusion Criteria: * Patient with invasive breast carcinoma stage T1 or T2 and / or in situ (any histological type) proved on histopathological diagnosis. * Patient with an indication of total mastectomy. * Patient without preoperative indication of adjuvant radiotherapy according to regional and / or national guidelines. * Disease located more than 2 cm from the nipple after complete clinical and radiologic breast evaluation (mammography, ultrasound +/- MRI). * Initial breast cancer or recurrence. * Patient wishing to receive immediate breast reconstruction. * WHO performance \< or = 2. * Patient older than 40 years. * For patients of childbearing age, use an effective contraceptive methods for the duration of the study. * For patients of childbearing potential, negative pregnancy test available before inclusion. * Patient affiliated to a social health insurance in France. * Patient who signed informed consent before enrollment in the study and before any specific procedure for the study. Exclusion Criteria : * Positive node on physical examination or proved by cytology. * Combination of 2 predictive factors of postoperative radiotherapy : macroscopic multifocal, grade 2 or 3, vascular emboli, overexpressed HER2 (human epidermal growth factor receptor-2), triple negative (Estrogen Receptor, Progesterone Receptor and HER2 negative). * Neoadjuvant treatment for the current disease. * Patient with bilateral breast cancer. * Paget disease. * T3 or T4 carcinoma. * Metastatic breast cancer (disease staging realized according to national or regional guidelines). * Breast hypertrophy requiring a nipple support flap. * Nursing or pregnant woman. * Patient participating in any other interventional clinical study. * Any psychological, familial, geographic or social situation not to comply with medical monitoring and/or procedures in the study protocol. * Patient protected by law.